|
Real-time Estimate
Cboe BZX
10:41:27 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 20.80 USD | -3.48% |
|
-5.76% | -70.18% |
| 09-30 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| 09-21 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
Company Valuation: Structure Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,991 | 1,553 | 4,809 | 1,537 | - | - |
| Change | - | -22.02% | 209.65% | -68.04% | - | - |
| Enterprise Value (EV) 1 | 1,991 | 669.4 | 3,362 | 569.6 | 977.5 | 1,535 |
| Change | - | -66.38% | 402.31% | -83.06% | 71.62% | 56.99% |
| P/E | -50.3x | -34.8x | -86.9x | -13.3x | -9.86x | -12.8x |
| PBR | - | 5.39x | 9.75x | 4.23x | 7.07x | 24.8x |
| PEG | 0.6x | 9.4x | -33.89x | -0x | -0.3x | 0.6x |
| Capitalization / Revenue | - | - | - | 36.9x | 33,811x | 10.1x |
| EV / Revenue | - | - | - | 13.7x | 21,508x | 10.1x |
| EV / EBITDA | - | -4.26x | -11.8x | -1.26x | -1.91x | -2.91x |
| EV / EBIT | -19.4x | -4.23x | -11.7x | -1.26x | -1.8x | -3.51x |
| EV / FCF | -24.4x | -5.68x | -14.9x | -1.52x | -2.53x | -3.37x |
| FCF Yield | -4.1% | -17.6% | -6.72% | -65.8% | -39.5% | -29.7% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.81 | -0.78 | -0.8 | -1.616 | -2.186 | -1.69 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 41.67 | 0.0454 | 152.6 |
| EBITDA 1 | - | -157.2 | -285.5 | -451.7 | -511.6 | -527.9 |
| EBIT 1 | -102.8 | -158.2 | -286.8 | -452 | -544.2 | -436.8 |
| Net income 1 | -89.62 | -122.5 | -141.2 | -313.8 | -471 | -336.7 |
| Net Debt 1 | - | -883.5 | -1,446 | -967.2 | -559.2 | -2.073 |
| Reference price 2 | 40.76 | 27.12 | 69.55 | 21.55 | 21.55 | 21.55 |
| Nbr of stocks (in thousands) | 48,855 | 57,261 | 69,139 | 71,310 | - | - |
| Announcement Date | 3/8/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -13.33x | 13.67x | -1.26x | -.--% | 1.54B | |
| 17.08x | 6.33x | 12.4x | 1.75% | 63.48B | |
| 30.03x | 7.96x | 26.08x | 0.05% | 54.55B | |
| 37.03x | 6.57x | 19.63x | 0.87% | 53.59B | |
| 35.05x | 3.37x | 14.55x | -.--% | 44.75B | |
| 48.28x | 5.55x | 30.42x | -.--% | 41.62B | |
| -19.33x | 186.93x | -20.57x | -.--% | 39.91B | |
| 30.28x | 7.94x | 20.6x | 0.4% | 32.47B | |
| 36.51x | 6.64x | 22.27x | -.--% | 26.7B | |
| 26.96x | 5.67x | 14.71x | -.--% | 23.36B | |
| Average | 22.86x | 25.06x | 13.88x | 0.31% | 38.2B | |
| Weighted average by Cap. | 26.39x | 25.19x | 15.61x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GPCR Stock
- Valuation Structure Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
